Everyone.org

Making medicine access fair is still largely uncharted territory, and after 8 years of experience, we’ve learned one thing: things will go wrong. But there’s always a solution. A few months ago, we arranged for an ALS patient in the U.S. to receive a medicine only available in Japan. Everything was set—until a shipping issue left the medicine stuck on the other end of the U.S. With the clock ticking, one of us personally stepped in to ensure it was delivered. It's not something we can do every time, but urgent is urgent, and we get it. Our commitment is to helping patients. And good luck to all the hurdles that try to stop us. 💪💪💪  #HealthAccess #healthequity #patientstories #ALS #teameveryone #shipping #problemsolving  #creativeproblemsolving  #dreamteam #deliver

12.5 days. That’s how fast we’re making medicine access a reality for patients worldwide. Compare that to 10+ years of waiting for approvals and ask yourself: how many lives can’t afford to wait? From continents to communities, the impact is real. And this is just the beginning. 🌍💊 You can be part of this change. Help a patient today—donate to the Everyone.org Foundation via foundation.everyone.org . ❤️ #donation #teameveryone #impactreport #2024

We’re officially a Certified B Corporation! 🌍✨ But becoming a B Corp isn’t something you achieve on your own. This milestone was made possible thanks to the patients we serve, the doctors who trust us, the partners who collaborate with us, and our incredible team who work tirelessly to change how people access healthcare worldwide. A special shoutout goes to Rana O., whose dedication and hard work led us through the rigorous certification process. 🏆 For us, B stands for Becoming—a commitment to keep improving every day, not just for our mission but for everyone impacted by what we do. 💪 More about our B Corp Certification here: https://lnkd.in/gSijxesd #BCorp #CertifiedBCorporation #Teamwork #HealthcareAccess #SocialImpact #BetterTogether #teameveryone #bstandsforbecoming

Even after a medicine is approved, it can take months or years to be widely adopted. However, some doctors are quicker to embrace new treatments, being more open to innovation and less risk-averse. What is it that makes some doctors more likely to be early adopters? Inspired by research from Ágnes Lublóy, we've simplified the profile of an early adopter medical professional. While these traits aren’t absolute and more factors play a role, this profile highlights the characteristics of doctors who may offer second opinions or be able to offer you the newest treatment options when needed. What do you think drives faster adoption of novel medicines? Share below 👇 #teameveryone #earlyadopters #medicineuptake #novelmedicines #newtreatments #doctors #medicineaccess

Hey Albert Bourla Paul Hudson Emma Walmsley Vas Narasimhan Joaquin Duato  - congratulations on making the Top 5 on this year’s Access to Medicines Index #ATMI24 from all of us at Everyone.org ! 🏆 Expanding medicine access looks good on you! But as top business leaders, you know that when you’re on a roll, you don’t slow down. You push harder. Medicine access deserves the same growth mindset. So, how will you reach more patients with your medicines next year? Here are just a couple of ideas off the tops of our heads: ✅ Donate to the Everyone.org Foundation (https://bit.ly/3Zv6Txh). By donating (e.g. your corporate Christmas gifts budget?), you enable us to bring life-saving medicines to patients in overlooked communities worldwide within DAYS. That's better than sending another pair of branded Christmas socks to Josh in the UK division, isn't it? Sorry, Josh. ✅ #callAart - Aart van Riel will help you set up a plug-and-play access program with us, so you can instantly expand your health equity efforts. Close to 3 Million patients come to our platform every year to find medicines that aren't available in their countries. We're not selfish, we'll connect you! Let’s make top 5 even brighter next year! Pfizer Sanofi GSK Novartis AstraZeneca Johnson & Johnson #medicineaccess #accesstomedicinefoundation #partnerships #donations #christmasbudget #sorryjosh #ATMI24 #accesstomedicines #pharma

Hey Dave Ricks, Ken Keller, Rob Davis, Daniel O'Day, Gary Hendler, Thomas Schinecker – we saw your rankings in this year’s Access to Medicine Index #ATMI24. Bottom half? Yikes. 😬 We get it – medicine access is a beast. It’s overwhelming. But here’s the deal: if we at Everyone.org can make it happen, YOU can, too. Here are just a few ideas for improving your ranking next year: ✅ Donate to the Everyone.org Foundation (https://bit.ly/3Zv6Txh). Donations enable us to bring life-saving medicines to patients in overlooked communities worldwide within DAYS. That's better than using your corporate Christmas gifts budget to send another pair of branded socks to Josh in the UK division. Sorry, Josh. ✅ #callAart - Aart van Riel will help you set up a plug-and-play access program with us. Close to 3 Million patients come to our platform every year to find medicines that aren't available in their countries. We're not selfish, we can connect you. You could reach exponentially more patients in underserved markets, instead of just the...10?...you reached this year. After all, it’s about the patients, right? 👀 See you in the top 5 next year? 👀 Eli Lilly and Company Daiichi Sankyo Merck Group Gilead Sciences Eisai Co., Ltd. Roche #medicineaccess #teameveryone #christmasbudget #patientsfirst #donations #partnerships #sorryjosh #accesstomedicines #pharma #givingtuesday

👏 Congratulations to one of our co-founders Bernard Muller on this well-deserved recognition! 👏 He never ceases to inspire us - as a passionate advocate in the fight against ALS, a relentless champion of research advancing initiatives, and a stellar example of the unstoppable power of human spirit and creativity!

Every day counts when it comes to access to life-saving medicines. In the EU, an EFPIA - European Federation of Pharmaceutical Industries and Associations  report reveals that reducing the time from CHMP recommendation to EMA approval by just 12 days could save 3,300 years of potential life. Behind that number lie untold stories of health restored, connections strengthened, and lives transformed. The cost of delays in medicine approval isn’t just about numbers—it’s about the priceless moments patients and their families lose each day they wait. These delays mean: • Lost moments of independence, well-being, and time with loved ones • Worsening health and emotional strain, impacting entire families • Greater pressure on healthcare systems and higher costs, felt by all • Lost potential for patients to engage in their communities, workplaces, and lives. Let’s work together to reduce these delays and ensure that patients don’t lose precious time—time that could be spent living with dignity, independence, and hope. #HealthcareAccess #PatientAdvocacy #InnovationInHealthcare #healthequity #teameveryone

Want your team to feel truly proud of where they work? This Christmas, let actions speak louder than stocking fillers. Instead of giving your team more "stuff" they don't really need, ❤️make a donation to the Everyone.org Foundation❤️ on their behalf. https://lnkd.in/eSbFtEjh This is the most impactful way to change lives and create fair medicine access. 100% of donations go directly to patients, helping them access critical treatments TODAY that could otherwise take YEARS to reach their countries. Now that’s a Christmas gift that makes a real difference. #CorporateGiving #HolidayBudget #MeaningfulGifts #AccessToMedicine #HealthcareEquity #EveryoneOrg #ChristmasGiving

🚨 Big News for Alzheimer’s Patients in Europe The CHMP has officially recommended Leqembi (lecanemab) for treating early Alzheimer’s disease. And this matters, because it’s the first treatment in Europe that may slow disease progression. But here’s the reality: The waiting isn’t over. 🔗 What happens next: - The European Commission must make Leqembi’s approval official—this takes over two months. - After that, each EU country begins its own process for pricing, reimbursement, and local launch. On average, this can take as little as 133 days in Germany or as long as 899 days in Romania, highlighting the stark inequalities still present across Europe. ⏳ Why waiting is an issue: Leqembi is only effective in the early stages of Alzheimer’s, a window that typically lasts 2–4 years. It’s already been nearly two years since Leqembi’s first FDA approval, and many patients who could have benefited have progressed beyond this critical stage. For those still eligible, every single day counts. ✨At Everyone.org, we believe waiting shouldn’t be part of the treatment plan. Patients can access Leqembi now, regardless of where they live. Health equity stats here: https://everyone.org/ #Alzheimers #Leqembi #AccessToMedicine #HealthcareEquity #EveryoneOrg #CHMP #Alzheimernederland #dementie #teameveryone